The Initial Experience of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in Latvia

Simple item page
dc.contributor.authorKrigere, Anna
dc.contributor.authorKalejs, Verners Roberts
dc.contributor.authorKaulins, Ricards
dc.contributor.authorRudzitis, Ainars
dc.contributor.authorBondare, Līga
dc.contributor.authorSablinskis, Matiss
dc.contributor.authorLejnieks, Aivars
dc.contributor.authorKigitovica, Dana
dc.contributor.authorKurzyna, Marcin
dc.contributor.authorSkride, Andris
dc.contributor.institutionDepartment of Internal Diseases
dc.date.accessioned2024-04-02T08:45:01Z
dc.date.available2024-04-02T08:45:01Z
dc.date.issued2024-03-30
dc.descriptionPublisher Copyright: © 2024 by the authors.
dc.description.abstractBackground: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent pulmonary hypertension after pulmonary endarterectomy (PEA) include targeted medical therapy and balloon pulmonary angioplasty (BPA). BPA is an emerging treatment modality that has been reported to improve functional capacity, pulmonary hemodynamics, and right ventricular function. Reports from expert centers are promising, but more data are needed to make the results more generalizable. Materials and Methods: We conducted a prospective analysis of nine consecutive CTEPH patients who underwent balloon pulmonary angioplasty (BPA) sessions at Pauls Stradins Clinical University Hospital in Riga, Latvia between 1 April 2022 and 1 July 2023. We assessed World Health Organization (WHO) functional class, 6 min walk distance (6MWD), blood oxygen saturation (SpO2), brain natriuretic peptide (BNP) level at baseline and 3 months after the first BPA session. For two patients on whom repeated BPA sessions were performed, we additionally assessed cardiac output (CO), pulmonary vascular resistance (PVR), and mean pulmonary artery pressure (mPAP). Results: A total of 12 BPA procedures for nine patients were performed; repeated BPA sessions were performed for two patients. Our results show a reduction in BNP levels and improvement in WHO functional class, 6MWD, and SpO2 after the first BPA session. Improvement in 6MWD was statistically significant. Additionally, an improvement in pulmonary hemodynamic parameters was observed. Conclusions: Our data show that BPA is an effective interventional treatment modality, improving both the pulmonary hemodynamics and functional status. Moreover, BPA is safe and excellently tolerated.en
dc.description.statusPeer reviewed
dc.format.extent14
dc.format.extent650775
dc.identifier.citationKrigere, A, Kalejs, V R, Kaulins, R, Rudzitis, A, Bondare, L, Sablinskis, M, Lejnieks, A, Kigitovica, D, Kurzyna, M & Skride, A 2024, 'The Initial Experience of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in Latvia', Medicina (Kaunas), vol. 60, no. 4, 568. https://doi.org/10.3390/medicina60040568
dc.identifier.doi10.3390/medicina60040568
dc.identifier.issn1010-660X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/15409
dc.identifier.urlhttps://www.mdpi.com/1648-9144/60/4/568
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85191352161&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofMedicina (Kaunas)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLatvia
dc.subjectballoon pulmonary angioplasty
dc.subjectchronic thromboembolic pulmonary hypertension
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral Medicine
dc.titleThe Initial Experience of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in Latviaen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
medicina-60-00568.pdf
Size:
635.52 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure